Protocol Ledger

NCT05676931 · Phase II · ACTIVE NOT RECRUITING

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Interventional Phase II clinical trial protocol NCT05676931 sponsored by Gilead Sciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-21 Enrollment: 400 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05676931
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)400 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05676931
Protocol FieldVerified Registry Value
NCT IdentifierNCT05676931
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment400 participants (ESTIMATED)
Registered Start Date2023-02-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05676931
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Northwestern Memorial and Lurie Cancer CenterChicago, ILOpen Hospital Dossier ->
Henry Ford HospitalDetroit, MIOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI